Previous Close | 902.50 |
Open | 899.78 |
Bid | 906.67 x 100 |
Ask | 908.85 x 100 |
Day's Range | 891.93 - 912.98 |
52 Week Range | 262.20 - 974.00 |
Volume | |
Avg. Volume | 53,877,886 |
Market Cap | 2.269T |
Beta (5Y Monthly) | 1.73 |
PE Ratio (TTM) | 76.21 |
EPS (TTM) | 11.91 |
Earnings Date | May 22, 2024 - May 27, 2024 |
Forward Dividend & Yield | 0.16 (0.02%) |
Ex-Dividend Date | Mar 05, 2024 |
1y Target Est | 904.36 |
Subscribe to Yahoo Finance Plus to view Fair Value for NVDA
Nvidia (NVDA) shares are trading lower for the second consecutive day, despite recent headlines that have fueled stock gains, such as the release of its new Blackwell product line-up. Yahoo Finance's Josh Lipton and Jared Blikre assess whether the company's performance could merely comprise a consolidation phase as the stock reaches new highs. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith
Artificial intelligence can find hidden signals in data across healthcare, and companies like Nvidia are leaning into what this can mean. For example, it announced two dozen new AI-powered tools last week for areas including biotechnology and drug discovery. And Nvidia is not alone. Century Health is a new startup also getting in on the action. It's applying AI to clinical data to uncover new applications for drugs. It's working with pharmaceutical companies and researchers, initially at Yale an
Small caps outperformed again in the stock market today as the first quarter draws to a close. Bitcoin jumped 3%, while oil prices rose.